Print this page
Kidney Cancer
-
A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab versus Relatlimab and Nivolumab in Participants with Unresectable or Metastatic Melanoma.
Protocol: 092402Principal Investigator:
- Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer.
Protocol: 082401Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Urinary Bladder -
A Phase 1, Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®819 in Subjects with Relapsed or Refractory Clear Cell Renal Cell Carcinoma.
Protocol: 082409Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Kidney -
Project Every Child: A Registry, Eligibility Screening, Biology and Outcome Study.
Protocol: 111509Principal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Any Site -
A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety
of UGN-104, a Novel Formulation of UGN-101, for the Treatment of Patients With Low-grade Upper Tract Urothelial Cancer (LG-UTUC)
Protocol: 082508Principal Investigator:
- Saum Ghodoussipour
Applicable Disease Sites: Other Urinary -
A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of
Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients
With Advanced Clear Cell Renal Cell Carcinoma
Protocol: 082510Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Kidney -
A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab versus Relatlimab and Nivolumab in Participants with Unresectable or Metastatic Melanoma.
Protocol: 092402Principal Investigator:
- Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT).
Protocol: 112504Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Any Site -
Project Every Child: A Registry, Eligibility Screening, Biology and Outcome Study.
Protocol: 111509Principal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Any Site -
Randomized Study of DOC1021 Dendritic Cell Immunotherapy in Combination with Standard of Care for Newly Diagnosed Adult Glioblastoma
Protocol: 142501Principal Investigator:
- Morana Vojnic
Applicable Disease Sites: Brain and Nervous System -
A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Cancers of the Stomach, Breast, Lung and Cervix.
Protocol: 192004Principal Investigator:
- Christian Hinrichs
Applicable Disease Sites: Any Site
Breast
Cervix
Lung
Stomach -
A Feasibility Study of E7 TCR-T Cell Induction Therapy for Locoregionally Advanced HPV-Associated Cancers.
Protocol: 192104Principal Investigator:
- Christian Hinrichs
Applicable Disease Sites: Breast
Cervix
Lip, Oral Cavity and Pharynx
Other Female Genital
Other Male Genital
Stomach -
A Phase II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers.
Protocol: 192204Principal Investigator:
- Christian Hinrichs
Applicable Disease Sites: Anus
Cervix
Larynx
Lip, Oral Cavity and Pharynx
Other Female Genital
Other Male Genital -
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT).
Protocol: 112504Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Any Site -
Randomized Study of DOC1021 Dendritic Cell Immunotherapy in Combination with Standard of Care for Newly Diagnosed Adult Glioblastoma
Protocol: 142501Principal Investigator:
- Morana Vojnic
Applicable Disease Sites: Brain and Nervous System -
A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Cancers of the Stomach, Breast, Lung and Cervix.
Protocol: 192004Principal Investigator:
- Christian Hinrichs
Applicable Disease Sites: Any Site
Breast
Cervix
Lung
Stomach